top of page

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Clinicaltrials.gov ID

NCT02628067

Status

Recruiting

Study Type

Interventional, Phase 2

Sponsor

Merck Sharp & Dohme LLC

Start Date

December 17, 2015

Anticipated End Date

October 1, 2026

Study Contact

Merck Contact

Phone Number:1-888-577-8839


Merck Canada Contact

Phone Number: 514-428-8600 / 1-800-567-2594

About the Study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Conditions

  • Advanced Cancer

  • Anal Carcinoma

  • Anal Cancer

  • Biliary Cancer

  • Cholangiocarcinoma

  • Bile Duct Cancer

  • Neuroendocrine Tumor

  • Carcinoid Tumor

  • Endometrial Carcinoma

  • Endometrial Cancer

  • Cervical Carcinoma

  • Cervical Cancer

  • Vulvar Carcinoma

  • Vulvar Cancer

  • Small Cell Lung Carcinoma

  • Small Cell Lung Cancer (SCLC)

  • Mesothelioma

  • Thyroid Carcinoma

  • Thyroid Cancer

  • Salivary Gland Carcinoma

  • Salivary Gland Cancer

  • Salivary Cancer

  • Parotid Gland Cancer

  • Advanced Solid Tumors

  • Colorectal Carcinoma

Inclusion/Exclusion Criteria?

Primary, Secondary, Other Outcome Measures??

Locations in Canada

  • Merck Canada, Kirkland, Quebec, H9H 4M7, Canada

Apply Now

About the Study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Conditions

  • Advanced Cancer

  • Anal Carcinoma

  • Anal Cancer

  • Biliary Cancer

  • Cholangiocarcinoma

  • Bile Duct Cancer

  • Neuroendocrine Tumor

  • Carcinoid Tumor

  • Endometrial Carcinoma

  • Endometrial Cancer

  • Cervical Carcinoma

  • Cervical Cancer

  • Vulvar Carcinoma

  • Vulvar Cancer

  • Small Cell Lung Carcinoma

  • Small Cell Lung Cancer (SCLC)

  • Mesothelioma

  • Thyroid Carcinoma

  • Thyroid Cancer

  • Salivary Gland Carcinoma

  • Salivary Gland Cancer

  • Salivary Cancer

  • Parotid Gland Cancer

  • Advanced Solid Tumors

  • Colorectal Carcinoma

Interventions

BIOLOGICAL:

  • pembrolizumab

Locations in Canada

  • Merck Canada, Kirkland, Quebec, H9H 4M7, Canada

bottom of page